Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer - Related Studies

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

This study has been completed.

Study NCT00003809. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Head and Neck Cancer

2	Additional conditions recognized in this trial
		Head and Neck Neoplasms

3	More general conditions related to this trial
		Neoplasms
		Neoplasms by Site

4	Interventions listed in this trial
		cetuximab
		cisplatin

5	Additional drug interventions recognized in this trial
		Antibodies, Monoclonal

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Eastern Cooperative Oncology Group
		National Cancer Institute (NCI)